Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 9/20 | 0.41 |
| ▸ | RAB9A | P51151 | 9/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.40 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL256207 | 0.78 | CYP11B1 (0.43) | CYP11B1CYP11B2NPC1RAB9AKMT2A | |
| SCHEMBL3658419 | 0.76 | CYP11B1 (0.42) | CYP11B1CYP11B2NPC1RAB9AKMT2A | |
| SCHEMBL25045525 | 0.76 | CYP11B1 (0.42) | CYP11B1CYP11B2NPC1RAB9AKMT2A | |
| SCHEMBL13791629 | 0.76 | CYP1A2 (0.62) | CYP11B1CYP11B2NPC1RAB9AKMT2A | |
| SCHEMBL21140432 | 0.73 | CYP11B1 (0.47) | CYP11B1CYP11B2NPC1RAB9AKMT2A | |
| SCHEMBL16785526 | 0.73 | NPC1 (0.42) | CYP11B1CYP11B2NPC1RAB9AKMT2A | |
| SCHEMBL3536463 | 0.73 | NPC1 (0.45) | CYP11B1CYP11B2NPC1RAB9AKMT2A | |
| SCHEMBL27837439 | 0.72 | CYP11B1 (0.52) | CYP11B1CYP11B2NPC1RAB9AKMT2A | |
| SCHEMBL15839015 | 0.71 | CYP11B2 (0.58) | CYP11B1CYP11B2CYP1A2CYP2A6CYP17A1 | |
| SCHEMBL24339586 | 0.71 | NPC1 (0.41) | CYP11B1CYP11B2NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155334-A1 | NOVEL PROCESSES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155334-A1 | NOVEL PROCESSES | CYP4A11, CYP4F11, CYP4F3 | CYP11B1 9/4885CYP11B2 5/4885NPC1 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.